STAT3 and non-small cell lung carcinoma: However, because numerous TKs share a common ability to induce downstream signaling effectors, nintedanib-treated NSCLC cells can engage feedback activation mechanisms such as STAT3, which are capable of promoting cell survival and limiting overall drug response in tumor cells themselves.